Iterum Therapeutics plc (ITRMF) Common Equity (2017 - 2025)

Iterum Therapeutics has reported Common Equity for 9 years, with the latest figure at -$7.4 million in Q3 2025.

• On a quarterly basis, Common Equity rose 35.86% year-over-year to -$7.4 million in Q3 2025; TTM through Sep 2025 was -$7.4 million, a 35.86% increase from a year earlier, with the FY2024 full-year figure at -$4.1 million, up 36.26% from the prior year.
• Common Equity was -$7.4 million for Q3 2025 at Iterum Therapeutics, down from -$3.9 million in the prior quarter.
• The five-year high for Common Equity was $52.4 million in Q3 2021, with the low at -$11.5 million in Q3 2024.
• Average Common Equity over 5 years is $16.4 million, with a median of $7.1 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Common Equity jumped 199.36% in 2021, then tumbled 435.29% in 2024.
• Over 5 years, Common Equity stood at $50.2 million in 2021, then slumped by 44.26% to $28.0 million in 2022, then sank by 122.87% to -$6.4 million in 2023, then jumped by 36.26% to -$4.1 million in 2024, then slumped by 80.86% to -$7.4 million in 2025.
• The last three Common Equity figures came in at -$7.4 million (Q3 2025), -$3.9 million (Q2 2025), and -$2.6 million (Q1 2025), per Business Quant data.